Sun Pharma Q4 Results Cons PAT falls 19% YoY to Rs 2,154 cr; Rs 5.5/sh dividend announced https://t.co/m9WF8BjhtX
Sun Pharma Q4 results: Net profit falls 19% to ₹2,153.9 cr, revenue up 8%. Check details here #SunPharma #Q4Results #CorporateEarning #Q4FY25 | @himanshuthk20 https://t.co/OQ0ycvZFhK
#Q4WithETNOW | Sun Pharma reports its Q4 numbers! @SunPharma_Live #EarningsWithETNOW #StockMarket #Nifty https://t.co/ZFmvRhvMY7
Strides Pharma, Emcure Pharma, and Sun Pharma have reported their financial results for the fourth quarter. Strides Pharma posted a net profit of ₹85.6 crore, a substantial increase from ₹10.4 crore year-over-year (YoY), with revenue rising 14% to ₹1,190 crore and EBITDA up 6.5% to ₹217.2 crore. However, its margin declined to 18.3% from 19.6%. Emcure Pharma reported a 64.4% increase in net profit to ₹189 crore and a 19.5% rise in revenue to ₹2,116 crore YoY. Sun Pharma's consolidated net profit fell 19% YoY to ₹2,153.9 crore, missing estimates of ₹2,934 crore, while revenue increased 8% to ₹12,958.8 crore, slightly below the expected ₹13,039.2 crore. EBITDA was ₹3,715.9 crore, marginally above the estimated ₹3,618 crore, with a margin of 28.7%. Sun Pharma also declared a dividend of ₹5.50 per share.
